The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 6-4 that a clinical trial failed to prove the drug is effective in patients with ALS.
The FDA is not required to follow the committee’s recommendations and is expected to make a final decision on the drug’s approval status by June 29.
Editor’s note: This article was updated March 31 at 5:24 p.m.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
